Genfit S.A. (EPA: GNFT)

Market Cap	172.52M
Revenue (ttm)	80.47M
Net Income (ttm)	22.27M
Shares Out	49.86M
EPS (ttm)	0.44
PE Ratio	7.92
Forward PE	25.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,716
Open	3.470
Previous Close	3.500
Day's Range	3.400 - 3.495
52-Week Range	3.025 - 5.860
Beta	1.10
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 20, 2024

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 159
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT

Financial Performance

In 2023, Genfit's revenue was 34.48 million, an increase of 31.38% compared to the previous year's 26.25 million. Losses were -28.89 million, 21.8% more than in 2022.